Pyridinylimidazole based p38 MAP kinase inhibitors
Paul F Jackson1, James L Bullington
1Discovery Research, Johnson Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. pjackso3@prdus.jnj.com
Current Topics in Medicinal Chemistry
|August 13, 2002
Summary
Pyridinylimidazole compounds are potent inhibitors of p38 MAP kinase, a key player in inflammatory diseases like rheumatoid arthritis. These compounds are crucial for understanding immune responses and central nervous system disorders.
Area of Science:
- Pharmacology
- Immunology
- Neuroscience
Background:
- p38 MAP kinase is implicated in inflammatory and immunological disorders, including rheumatoid arthritis.
- Pyridinylimidazole compounds were the first potent inhibitors identified for this kinase.
- This compound class is extensively studied and has led to clinical trial candidates.
Purpose of the Study:
- To summarize the significance of pyridinylimidazole compounds as p38 MAP kinase inhibitors.
- To highlight their role in understanding inflammatory and immunological pathways.
- To underscore their emerging importance in central nervous system disorder research.
Main Methods:
- Review of existing literature on pyridinylimidazole compounds and p38 MAP kinase.
- Analysis of synthetic modifications and clinical trial progression.
- Examination of studies investigating p38 kinase in immune and neurological functions.
Main Results:
- Pyridinylimidazoles represent a foundational and widely studied class of p38 MAP kinase inhibitors.
- These inhibitors have facilitated research into the kinase's role in the immune system.
- Recent research utilizes these compounds to explore p38 kinase involvement in CNS disorders.
Conclusions:
- Pyridinylimidazole compounds are vital tools in p38 MAP kinase research.
- Their synthetic development has advanced therapeutic strategies for inflammatory conditions.
- Their application is expanding to investigate neurological disease mechanisms.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...